Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome Image Cannabis News October 1, 2024 SciSparc receives FDA approval for a Phase IIb trial of a cannabinoid based treatment for Tourette Syndrome. SciSparc Ltd., a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company Cannabis Technology News by Rolando Garcia